Clinical trials: Urticaria Chronic
Chronic Spontaneous Urticaria
A Study to Investigate the Use of Benralizumab in Patients With Chronic Spontaneous Urticaria Who Are Symptomatic Despite the Use of Antihistamines (ARROYO)
The purpose of this study is to investigate the use of benralizumab is effective in the treatment of chronic spontaneous urticaria (CSU) who are symptomatic despite the use of antihistamines.
- Trial name
- ARROYO (NCT04612725)
- Testing
- Benralizumab
- Where
- 40 sites in United States, Bulgaria and 5 more
- Volunteers
- 159 people
- Sponsor
- AstraZeneca
Chronic Spontaneous Urticaria (CSU)
A Study of MG-K10 in Chronic Spontaneous Urticaria
This study is a multicenter, randomized, double-blind, placebo-controlled phase III clinical trial aimed at evaluating the efficacy and safety of MG-K10 humanized monoclonal antibody injection in CSU trial participants with poor…
- Trial name
- NCT07546487
- Testing
- MG-K10 Humanized Monoclonal Antibody Injection
- Volunteers
- 226 people
- Sponsor
- Shanghai Mabgeek Biotech.Co.Ltd
Chronic Spontaneous Urticaria (CSU)
Study of CM512 Injection in Subjects With Chronic Spontaneous Urticaria(CSU)
This study is a multicenter, randomized, double-blind, placebo-controlled phase II clinical study to evaluate the efficacy, safety, pharmacokinetics, pharmacodynamics, and immunogenicity of CM512 in subjects with CSU.
- Trial name
- NCT07166211
- Testing
- CM512 injection
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Keymed Biosciences Co.Ltd
Chronic Spontaneous Urticaria
A Study to Describe the Real-world Effectiveness, Safety and Patterns of Use of Dupilumab in Patients With Chronic Spontaneous Urticaria
This is a decentralized study designed to describe the real-world effectiveness, safety, and patterns of use of dupilumab in patients with chronic spontaneous urticaria (CSU).
- Trial name
- DEDICATION (NCT07316114)
- Testing
- Dupilumab
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Sanofi
Chronic Urticaria
A Worldwide Antihistamine-Refractory Chronic Urticaria Patient Evaluation in Latin America and Canada (AWARE-LACan)
This is a non-interventional, multi-country, Latin American study utilizing a prospective single-cohort design. Eligible CU patients will be enrolled in the study and will be followed for 24 months (± 6 weeks).
- Trial name
- AWARE-LACan (NCT02626221)
- Testing
- Non Interventional Study
- Where
- 31 sites in Argentina, Brazil and 7 more
- Volunteers
- 497 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Urticaria, Idiopathic
Molecular Endotypes of Chronic Idiopathic Urticaria
This study plans to learn more about why some people with Chronic Idiopathic Urticaria (CIU) respond to treatment with omalizumab (Xolair).
- Trial name
- NCT04774315
- Testing
- Omalizumab
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Chronic Urticaria
Natural History of Chronic Urticaria
The purpose of this study is to examine the natural history of chronic urticaria in children and to identify the predictors for chronic urticaria remission.
- Trial name
- NHCU (NCT01284426)
- Where
- Thailand
- Volunteers
- 94 people
- Sponsor
- Mahidol University
Solar Urticaria
Omalizumab in Severe and Refractory Solar Urticaria
Solar urticaria is a rare disease, with a usual favourable outcome with photoprotection and with anti H1 histamines. Nevertheless, some cases can be severe and refractory to this usual treatment, leading to a large impact on…
- Trial name
- XOLUS (NCT02262130)
- Testing
- Omalizumab
- Where
- 13 sites in France
- Volunteers
- 10 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Cryopyrin Associated Periodic Syndrome
Adult Outcomes of Children With CAPS
The patients included in this study were followed up in the Internal Medicine and Paediatrics Departments of the Lille CHU, the Paediatric Rheumatology and Immunology Department of the Necker Enfant Malade Hospital in Paris and…
- Trial name
- CAPS (NCT04856540)
- Where
- France
- Volunteers
- 54 people
- Sponsor
- University Hospital, Lille
Chronic Inducible Urticaria
A Study Evaluating the Safety, Tolerability, and Efficacy of EVO756 in Adults With Chronic Inducible Urticaria
This phase 2a trial will evaluate the safety and efficacy of EVO756 in subjects with chronic inducible urticaria, including symptomatic dermographism and cold urticaria.
- Trial name
- NCT06603220
- Testing
- Oral EVO756 300 mg QD, Oral EVO756 50 mg BID
- Where
- 18 sites in United States
- Volunteers
- 30 people
- Sponsor
- Evommune, Inc.
Cryopyrin-associated Periodic Syndromes, Familial Cold Autoinflammatory Syndrome
Efficacy, Safety and Tolerability of ACZ885 in Pediatric Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease
This trial will provide long-term safety, efficacy and tolerability of ACZ885 in CAPS patients that completed the CACZ885D2307 study
- Conditions
- Cryopyrin-associated Periodic Syndromes, Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, Neonatal Onset Multisystem Inflammatory Disease
- Trial name
- NCT01576367
- Testing
- ACZ885
- Where
- 12 sites in Belgium, Canada and 5 more
- Volunteers
- 17 people
- Sponsor
- Novartis Pharmaceuticals
Allergic Rhinitis, Chronic Urticaria
Safety Study of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 1 to Less Than 6 Years Suffering From Allergic Rhinitis or Chronic Urticaria of Unknown Origin
The purpose of this study is to determine the safety of the oral formulation of levocetirizine in children ages 1 to less than 6 years old who suffer from allergic rhinitis or chronic urticaria of unknown origin.
- Trial name
- PAL (NCT00619801)
- Testing
- Levocetirizine
- Where
- 28 sites in United States
- Volunteers
- 173 people
- Sponsor
- UCB Pharma
Rhinitis, Allergic, Asthma, Allergic
Food-specific IgG4-guided Elimination Diets Improve Allergy Symptoms in Children
Allergic diseases in children are major public health concerns due to their widespread and rising prevalence. The most classic pathway to trigger allergy is type I allergy mediated by immunoglobulin E(IgE), but the role of…
- Conditions
- Rhinitis, Allergic, Asthma, Allergic, Conjunctivitis, Allergic, Atopic Dermatitis
- Trial name
- NCT06063044
- Where
- China
- Volunteers
- 407 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Chronic Urticaria
Cross-Cultural of the Validity, Reliability and Interpretability of Thai-version of Urticaria Control Test
Chronic urticaria symptoms commonly fluctuate from day by day. Consequently the clinical presentation of a patient in each visit is not representative of the current disease status.
- Trial name
- NCT02285049
- Testing
- Urticaria Control Test
- Where
- Thailand
- Volunteers
- 169 people
- Sponsor
- Mahidol University
Chronic Inducible Urticaria
A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines
This is a Phase 3, parallel group, placebo-controlled, double-blind, confirmatory study in patients with CINDU, with an optional Open-label Extension (OLE).
- Trial name
- NCT05976243
- Testing
- Remibrutinib
- Where
- 130 sites in United States, Argentina and 26 more
- Volunteers
- 362 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Spontaneous Urticaria, Cholinergic Urticaria
Study of Mechanism of Action of Ligelizumab (QGE031) in Patients With Chronic Urticaria
The purpose of the study is to investigate the mechanism of action for ligelizumab (QGE031) treatment in patients with chronic urticaria. The study has two parts.
- Conditions
- Chronic Spontaneous Urticaria, Cholinergic Urticaria, Cold Urticaria
- Trial name
- MASTER (NCT04513548)
- Testing
- Ligelizumab
- Where
- Germany
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Chronic Spontaneous Urticaria (CSU)
A Phase Ib/IIa Study Assessing the Rapid Onset Characteristics of TLL-018 for Moderate-to-Severe CSU With Inadequate Response to Second-Generation H1 Antihistamines
The goal of this clinical trial is to evaluate the rapid onset characteristics of TLL-018 in moderate-to-severe CSU with inadequate response to second-generation H1 antihistamines.
- Trial name
- NCT07665996
- Testing
- TLL-018
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Hangzhou Highlightll Pharmaceutical Co., Ltd
Chronic Inducible Urticaria
Phase 1b, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Chronic Inducible Urticaria
This phase 1b trial will evaluate the effects of EP262 in subjects with Chronic Inducible Urticaria (CIndU), including symptomatic dermographism and cold urticaria.
- Trial name
- CALM-CIndU (NCT06050928)
- Testing
- Oral EP262
- Where
- 15 sites in United States, Canada and 3 more
- Volunteers
- 33 people
- Sponsor
- Escient Pharmaceuticals, Inc
Chronic Urticaria
A Study to Assess the Efficacy and Safety of AK002 in Subjects With Antihistamine-Resistant Chronic Urticaria
This is a Phase 2a, open-label study to assess the effects of AK002
- Trial name
- CURSIG (NCT03436797)
- Testing
- AK002
- Where
- 4 sites in United States, Germany
- Volunteers
- 47 people
- Sponsor
- Allakos Inc.
Chronic Spontaneous Urticaria
Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects With Chronic Spontaneous Urticaria
Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects with Chronic Spontaneous Urticaria
- Trial name
- CALM-CSU (NCT06077773)
- Testing
- Oral EP262
- Where
- 48 sites in United States, Canada and 4 more
- Volunteers
- 113 people
- Sponsor
- Escient Pharmaceuticals, Inc